SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Robert A. Smith, Kimberly Andrews, Durado Brooks, Carol E. DeSantis, Stacey A. Fedewa, Joannie Lortet-Tieulent, Deana Manassaram-Baptiste, Otis W. Brawley, Richard C. Wender, Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening, CA: A Cancer Journal for Clinicians, 2016, 66, 1
  2. 2
    Mukesh Digambar Sonawane, Satish Balasaheb Nimse, Keum-Soo Song, Taisun Kim, Detection, quantification, and profiling of PSA: current microarray technologies and future directions, RSC Adv., 2016, 6, 9, 7599

    CrossRef

  3. 3
    S. Scott Sutton, E. David Crawford, Judd W. Moul, James W. Hardin, Eric Kruep, Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System, World Journal of Urology, 2016,

    CrossRef

  4. 4
    Maria P. Silva, João D. Barros-Silva, Joana Vieira, Susana Lisboa, Lurdes Torres, Cecília Correia, Márcia Vieira-Coimbra, Ana T. Martins, Carmen Jerónimo, Rui Henrique, Paula Paulo, Manuel R. Teixeira, NCOA2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer, Genes, Chromosomes and Cancer, 2016, 55, 4
  5. 5
    Cosimo De Nunzio, Fabrizio Presicce, Riccardo Lombardo, Fabiana Cancrini, Stefano Petta, Alberto Trucchi, Mauro Gacci, Luca Cindolo, Andrea Tubaro, Physical activity as a risk factor for prostate cancer diagnosis: a prospective biopsy cohort analysis, BJU International, 2016, 117, 2
  6. 6
    Idris Guessous, Stéphane Cullati, Stacey A. Fedewa, Claudine Burton-Jeangros, Delphine S. Courvoisier, Orly Manor, Christine Bouchardy, Prostate cancer screening in Switzerland: 20-year trends and socioeconomic disparities, Preventive Medicine, 2016, 82, 83

    CrossRef

  7. 7
    John S. Banerji, Erika M. Wolff, John D. Massman, Katherine Odem-Davis, Christopher R. Porter, John M. Corman, Prostate Needle Biopsy Outcomes in the Era of the U.S. Preventive Services Task Force Recommendation against Prostate Specific Antigen Based Screening, The Journal of Urology, 2016, 195, 1, 66

    CrossRef

  8. 8
    Sharanjot Saini, PSA and beyond: alternative prostate cancer biomarkers, Cellular Oncology, 2016,

    CrossRef

  9. 9
    Terri R. Fried, Shared Decision Making — Finding the Sweet Spot, New England Journal of Medicine, 2016, 374, 2, 104

    CrossRef

  10. 10
    C.J. Stimson, Prostate Cancer, 2016,

    CrossRef

  11. 11
    K Munkholm, L Peijs, M Vinberg, L V Kessing, A composite peripheral blood gene expression measure as a potential diagnostic biomarker in bipolar disorder, Translational Psychiatry, 2015, 5, 8, e614

    CrossRef

  12. You have free access to this content12
    Khaled El-Shami, Kevin C. Oeffinger, Nicole L. Erb, Anne Willis, Jennifer K. Bretsch, Mandi L. Pratt-Chapman, Rachel S. Cannady, Sandra L. Wong, Johnie Rose, April L. Barbour, Kevin D. Stein, Katherine B. Sharpe, Durado D. Brooks, Rebecca L. Cowens-Alvarado, American Cancer Society Colorectal Cancer Survivorship Care Guidelines, CA: A Cancer Journal for Clinicians, 2015, 65, 6
  13. 13
    Heidi A. Hanson, Ken R. Smith, Antoinette M. Stroup, C. Janna Harrell, An age–period–cohort analysis of cancer incidence among the oldest old, Utah 1973–2002, Population Studies, 2015, 69, 1, 7

    CrossRef

  14. You have free access to this content14
    Dragan Ilic, Walid Jammal, Pauline Chiarelli, Robert A. Gardiner, Suzanne Hughes, Dana Stefanovic, Suzanne K. Chambers, Assessing the effectiveness of decision aids for decision making in prostate cancer testing: a systematic review, Psycho-Oncology, 2015, 24, 10
  15. 15
    Vinayak Muralidhar, David R. Ziehr, Brandon A. Mahal, Yu-Wei Chen, Michelle D. Nezolosky, Vidya B. Viswanathan, Toni K. Choueiri, Christopher J. Sweeney, Quoc-Dien Trinh, Paul L. Nguyen, Association Between Older Age and Increasing Gleason Score, Clinical Genitourinary Cancer, 2015, 13, 6, 525

    CrossRef

  16. You have free access to this content16
    Robert A. Smith, Deana Manassaram-Baptiste, Durado Brooks, Mary Doroshenk, Stacey Fedewa, Debbie Saslow, Otis W. Brawley, Richard Wender, Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening, CA: A Cancer Journal for Clinicians, 2015, 65, 1
  17. 17
    Michael E. Chua, Patrick P. Tanseco, Jonathan S. Mendoza, Josefino C. Castillo, Marcelino L. Morales, Saturnino L. Luna, Configuration and validation of a novel prostate disease nomogram predicting prostate biopsy outcome: A prospective study correlating clinical indicators among Filipino adult males with elevated PSA level, Asian Journal of Urology, 2015, 2, 2, 114

    CrossRef

  18. You have free access to this content18
    Philippe D. Violette, Thomas Agoritsas, Paul Alexander, Jarno Riikonen, Henrikki Santti, Arnav Agarwal, Neera Bhatnagar, Philipp Dahm, Victor Montori, Gordon H. Guyatt, Kari A. O. Tikkinen, Decision aids for localized prostate cancer treatment choice: Systematic review and meta-analysis, CA: A Cancer Journal for Clinicians, 2015, 65, 3
  19. 19
    Catherine Tomko, Kimberly Davis, Samantha Ludin, Scott Kelly, Aaron Stern, George Luta, Kathryn L. Taylor, Decisional outcomes following use of an interactive web-based decision aid for prostate cancer screening, Translational Behavioral Medicine, 2015, 5, 2, 189

    CrossRef

  20. 20
    Jesse D. Sammon, Deepansh Dalela, Firas Abdollah, Toni K. Choueiri, Paul K. Han, Moritz Hansen, Paul L. Nguyen, Akshay Sood, Mani Menon, Quoc-Dien Trinh, Determinants of Prostate Specific Antigen Screening among Black Men in the United States in the Contemporary Era, The Journal of Urology, 2015,

    CrossRef

  21. You have free access to this content21
    Kumar Mukherjee, Richard Segal, Discussions with healthcare providers about prostate-specific antigen testing: evidence from the Behavioral Risk Factor Surveillance System in the USA, Journal of Pharmaceutical Health Services Research, 2015, 6, 1
  22. 22
    Bryan Leyva, Alexander Persoskie, Allison Ottenbacher, Jada G. Hamilton, Jennifer D. Allen, Sarah C. Kobrin, Stephen H. Taplin, Do Men Receive Information Required for Shared Decision Making About PSA Testing? Results from a National Survey, Journal of Cancer Education, 2015,

    CrossRef

  23. 23
    Hamide Sayar, Burak Besir Bulut, Abdulkadir Yasir Bahar, Mustafa Remzi Bahar, Nurten Seringec, Sefa Resim, Harun Çıralık, Does imprint cytology improve the accuracy of transrectal prostate needle biopsy?, Diagnostic Cytopathology, 2015, 43, 2
  24. 24
    Amanda F. Saltzman, Suhong Luo, Jeffery F. Scherrer, Kenneth D. Carson, Robert L. Grubb, M׳Liss A. Hudson, Earlier prostate-specific antigen testing in African American men—Clinical support for the recommendation, Urologic Oncology: Seminars and Original Investigations, 2015, 33, 7, 330.e9

    CrossRef

  25. 25
    John S. Luque, Siddhartha Roy, Yelena N. Tarasenko, Levi Ross, Jarrett Johnson, Clement K. Gwede, Feasibility Study of Engaging Barbershops for Prostate Cancer Education in Rural African-American Communities, Journal of Cancer Education, 2015, 30, 4, 623

    CrossRef

  26. 26
    Tianyu Zheng, Nickisha Pierre-Pierre, Xin Yan, Qun Huo, Alvin J.O. Almodovar, Felipe Valerio, Inoel Rivera-Ramirez, Elizabeth Griffith, David D. Decker, Sixue Chen, Ning Zhu, Gold Nanoparticle-Enabled Blood Test for Early Stage Cancer Detection and Risk Assessment, ACS Applied Materials & Interfaces, 2015, 7, 12, 6819

    CrossRef

  27. 27
    Bimal Bhindi, Muhammad Mamdani, Girish S. Kulkarni, Antonio Finelli, Robert J. Hamilton, John Trachtenberg, Alexandre R. Zlotta, Andrew Evans, Theodorus H. van der Kwast, Ants Toi, Neil E. Fleshner, Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates, The Journal of Urology, 2015, 193, 5, 1519

    CrossRef

  28. 28
    Sanxiong Xu, Zuozhang Yang, Jinyu Zhang, Yongxin Jiang, Yongbin Chen, Hongjun Li, Xuefeng Liu, Da Xu, Yanjin Chen, Yihao Yang, Ya Zhang, Dongxu Li, Junfeng Xia, Increased Levels of β-catenin, LEF-1, and HPA-1 Correlate with Poor Prognosis for Acral Melanoma with NegativeBRAFandNRASMutation inBRAFExons 11 and 15 andNRASExons 1 and 2, DNA and Cell Biology, 2015, 34, 1, 69

    CrossRef

  29. 29
    Richard M. Hoffman, Joann G. Elmore, Michael P. Pignone, Bethany S. Gerstein, Carrie A. Levin, Kathleen M. Fairfield, Knowledge and values for cancer screening decisions: Results from a national survey, Patient Education and Counseling, 2015,

    CrossRef

  30. 30
    Rachel Sparks, B. Nicolas Bloch, Ernest Feleppa, Dean Barratt, Daniel Moses, Lee Ponsky, Anant Madabhushi, Multiattribute probabilistic prostate elastic registration (MAPPER): Application to fusion of ultrasound and magnetic resonance imaging, Medical Physics, 2015, 42, 3, 1153

    CrossRef

  31. 31
    Ivan Platzek, Angelika Borkowetz, Marieta Toma, Thomas Brauer, Christoph Meissner, Katrin Dietel, Manfred Wirth, Michael Laniado, Multiparametric Prostate Magnetic Resonance Imaging at 3 T, Journal of Computer Assisted Tomography, 2015, 39, 5, 674

    CrossRef

  32. 32
    Chuigong Yu, Guojun Wu, Ruixiao Li, Lei Gao, Fan Yang, Yi Zhao, Jian Zhang, Rui Zhang, Jing Zhang, Libo Yao, Jianlin Yuan, Xia Li, NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer, Cancer Biology & Therapy, 2015, 16, 2, 287

    CrossRef

  33. 33
    Li Lu, Ni Fu, Xu Luo, Xiao-Yun Li, Xiao-Ping Li, Overexpression of cofilin 1 in prostate cancer and the corresponding clinical implications, Oncology Letters, 2015,

    CrossRef

  34. 34
    J. Quanico, J. Franck, J. P. Gimeno, R. Sabbagh, M. Salzet, R. Day, I. Fournier, Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers, Chem. Commun., 2015, 51, 22, 4564

    CrossRef

  35. 35
    Hasan Yilmaz, Seyfettin Ciftci, Ufuk Yavuz, Murat Ustuner, Ali Saribacak, Ozdal Dillioglugil, Percentage of free prostate-specific antigen (PSA) is a useful method in deciding to perform prostate biopsy with higher core numbers in patients with low PSA cut-off values, The Kaohsiung Journal of Medical Sciences, 2015, 31, 6, 315

    CrossRef

  36. 36
    Clement K. Gwede, Stacy N. Davis, Shaenelle Wilson, Mitul Patel, Susan T. Vadaparampil, Cathy D. Meade, Brian M. Rivers, Daohai Yu, Javier Torres-Roca, Randy Heysek, Philippe E. Spiess, Julio Pow-Sang, Paul Jacobsen, Perceptions of Prostate Cancer Screening Controversy and Informed Decision Making: Implications for Development of a Targeted Decision Aid for Unaffected Male First-Degree Relatives, American Journal of Health Promotion, 2015, 29, 6, 393

    CrossRef

  37. 37
    Jesse D. Sammon, Firas Abdollah, Anthony D’Amico, Matthew Gettman, Alexander Haese, Nazareno Suardi, Andrew Vickers, Quoc-Dien Trinh, Predicting Life Expectancy in Men Diagnosed with Prostate Cancer, European Urology, 2015, 68, 5, 756

    CrossRef

  38. 38
    D.A. Villaseñor Chávez, J. Guzmán Esquivel, Prevención cuaternaria, Revista Mexicana de Urología, 2015, 75, 3, 123

    CrossRef

  39. 39
    Y. S. M. Alajerami, K. M. Abushab, S. I. Alagha, A. M. Beeram, Ahmed Najim,   Roentgen, Prostate Cancer Diagnostic and Evaluation in Gaza-Strip, Palestine, Health, 2015, 07, 11, 1552

    CrossRef

  40. 40
    Breton Roussel, Gregory M. Ouellet, Supriya G. Mohile, William Dale, Prostate Cancer in Elderly Men, Clinics in Geriatric Medicine, 2015, 31, 4, 615

    CrossRef

  41. 41
    Heather Orom, Willie Underwood, D. Lynn Homish, Marc T. Kiviniemi, Gregory G. Homish, Christian J. Nelson, Zvi Schiffman, Prostate cancer survivors' beliefs about screening and treatment decision-making experiences in an era of controversy, Psycho-Oncology, 2015, 24, 9
  42. 42
    Eric H Kim, Gerald L Andriole, Prostate-specific antigen-based screening: controversy and guidelines, BMC Medicine, 2015, 13, 1, 61

    CrossRef

  43. 43
    Arnout R Alberts, Ivo G Schoots, Monique J Roobol, Prostate-specific antigen-based prostate cancer screening: Past and future, International Journal of Urology, 2015, 22, 6
  44. 44
    Michael J. Barry, Richard M. Wexler, Charles D. Brackett, Karen R. Sepucha, Leigh H. Simmons, Bethany S. Gerstein, Vickie L. Stringfellow, Floyd J. Fowler, Responses to a Decision Aid on Prostate Cancer Screening in Primary Care Practices, American Journal of Preventive Medicine, 2015, 49, 4, 520

    CrossRef

  45. 45
    Michael C. Soung, Screening for Cancer: When to Stop?, Medical Clinics of North America, 2015, 99, 2, 249

    CrossRef

  46. 46
    Vendula Pernikářová, Pavel Bouchal, Targeted proteomics of solid cancers: from quantification of known biomarkers towards reading the digital proteome maps, Expert Review of Proteomics, 2015, 12, 6, 651

    CrossRef

  47. 47
    Ryan C. Hutchinson, Daniel N. Costa, Yair Lotan, The economic effect of using magnetic resonance imaging and magnetic resonance ultrasound fusion biopsy for prostate cancer diagnosis, Urologic Oncology: Seminars and Original Investigations, 2015,

    CrossRef

  48. 48
    Mohammad Khalid Hararah, Craig Evan Pollack, Mary A. Garza, Hsin-Chieh Yeh, Diane Markakis, Darcy F. Phelan-Emrick, Jennifer Wenzel, Gary R. Shapiro, Lee Bone, Lawrence Johnson, Jean G. Ford, The Relationship Between Education and Prostate-Specific Antigen Testing Among Urban African American Medicare Beneficiaries, Journal of Racial and Ethnic Health Disparities, 2015, 2, 2, 176

    CrossRef

  49. 49
    Daniel S. Wang, Ashesh B. Jani, Musu Sesay, Caroline G. Tai, Daniel K. Lee, Katharina V. Echt, Michael G. Goodman, Kerry E. Kilbridge, Viraj A. Master, Video-based educational tool improves patient comprehension of common prostate health terminology, Cancer, 2015, 121, 5
  50. 50
    Hang Li, Hong Hu, Rui Wang, Yawei Zhang, Jiaqing Xiang, Quan Liu, Wei Shi, Yihua Sun, Haiquan Chen, When Should 99mTc Bone Scintigraphy Be Performed in cT1N0 Non-Small Cell Lung Cancer Patients?, Medicine, 2015, 94, 51, e2309

    CrossRef

  51. 51
    Idris Guessous, Jacques Cornuz, Why and how would we implement a lung cancer screening program?, Public Health Reviews, 2015, 36, 1

    CrossRef

  52. 52
    Nickisha Pierre-Pierre, Qun Huo, Recent Progress in Colloid and Surface Chemistry with Biological Applications, 2015,

    CrossRef

  53. You have free access to this content53
    Simon P. Kim, R. Jeffrey Karnes, Paul L. Nguyen, Jeanette Y. Ziegenfuss, R. Houston Thompson, Leona C. Han, Nilay D. Shah, Marc C. Smaldone, Cary P. Gross, Igor Frank, Christopher J. Weight, Timothy J. Beebe, Jon C. Tilburt, A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer, BJU International, 2014, 113, 5b
  54. 54
    Yuan Huang, Gong Cheng, Bianjiang Liu, Pengfei Shao, Chao Qin, Jie Li, Lixin Hua, Changjun Yin, A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients, BMC Urology, 2014, 14, 1, 8

    CrossRef

  55. 55
    Jaspreet Singh Batra, Swati Girdhani, Lynn Hlatky, A Quest to Identify Prostate Cancer Circulating Biomarkers with a Bench-to-Bedside Potential, Journal of Biomarkers, 2014, 2014, 1

    CrossRef

  56. You have free access to this content56
    Ted A. Skolarus, Andrew M.D. Wolf, Nicole L. Erb, Durado D. Brooks, Brian M. Rivers, Willie Underwood, Andrew L. Salner, Michael J. Zelefsky, Jeanny B. Aragon-Ching, Susan F. Slovin, Daniela A. Wittmann, Michael A. Hoyt, Victoria J. Sinibaldi, Gerald Chodak, Mandi L. Pratt-Chapman, Rebecca L. Cowens-Alvarado, American Cancer Society prostate cancer survivorship care guidelines, CA: A Cancer Journal for Clinicians, 2014, 64, 4
  57. 57
    Pedro Costa-Pinheiro, Hiten RH Patel, Rui Henrique, Carmen Jerónimo, Biomarkers and personalized risk stratification for patients with clinically localized prostate cancer, Expert Review of Anticancer Therapy, 2014, 14, 11, 1349

    CrossRef

  58. You have free access to this content58
    Robert A. Smith, Deana Manassaram-Baptiste, Durado Brooks, Vilma Cokkinides, Mary Doroshenk, Debbie Saslow, Richard C. Wender, Otis W. Brawley, Cancer screening in the United States, 2014: A review of current American Cancer Society guidelines and current issues in cancer screening, CA: A Cancer Journal for Clinicians, 2014, 64, 1
  59. 59
    Robert A. Smith, Counterpoint: Overdiagnosis in Breast Cancer Screening, Journal of the American College of Radiology, 2014, 11, 7, 648

    CrossRef

  60. 60
    Sara J. Knight, Decision Making and Prostate Cancer Screening, Urologic Clinics of North America, 2014, 41, 2, 257

    CrossRef

  61. 61
    Massimo Valerio, Ahmed El-Shater Bosaily, Mark Emberton, Hashim U. Ahmed, Defining the level of evidence for technology adoption in the localized prostate cancer pathway, Urologic Oncology: Seminars and Original Investigations, 2014, 32, 6, 924

    CrossRef

  62. 62
    Mafalda Almeida, Vera L. Costa, Natália R. Costa, João Ramalho-Carvalho, Tiago Baptista, Franclim R. Ribeiro, Paula Paulo, Manuel R. Teixeira, Jorge Oliveira, Ragnhild A. Lothe, Guro E. Lind, Rui Henrique, Carmen Jerónimo, Epigenetic regulation of EFEMP1 in prostate cancer: biological relevance and clinical potential, Journal of Cellular and Molecular Medicine, 2014, 18, 11
  63. 63
    Robert W. Sanson-Fisher, Catherine A. D'Este, Mariko L. Carey, Natasha Noble, Christine L. Paul, Evaluation of Systems-Oriented Public Health Interventions: Alternative Research Designs, Annual Review of Public Health, 2014, 35, 1, 9

    CrossRef

  64. 64
    Roman Gulati, Alex Tsodikov, Ruth Etzioni, Rachel A. Hunter-Merrill, John L. Gore, Angela B. Mariotto, Matthew R. Cooperberg, Expected population impacts of discontinued prostate-specific antigen screening, Cancer, 2014, 120, 22
  65. 65
    Saqib Javed, Stephen E.M. Langley, Importance of HOX genes in normal prostate gland formation, prostate cancer development and its early detection, BJU International, 2014, 113, 4
  66. 66
    Stacy N. Davis, Steven K. Sutton, Susan T. Vadaparampil, Cathy D. Meade, Brian M. Rivers, Mitul V. Patel, Javier F. Torres-Roca, Randy V. Heysek, Philippe Spiess, Julio Pow-Sang, Paul B. Jacobsen, Clement K. Gwede, Informed decision making among first-degree relatives of prostate cancer survivors: A pilot randomized trial, Contemporary Clinical Trials, 2014, 39, 2, 327

    CrossRef

  67. 67
    Monique J. Roobol, International Perspectives on Screening, Urologic Clinics of North America, 2014, 41, 2, 237

    CrossRef

  68. 68
    Richard M. Hoffman, Joann G. Elmore, Kathleen M. Fairfield, Bethany S. Gerstein, Carrie A. Levin, Michael P. Pignone, Lack of Shared Decision Making in Cancer Screening Discussions, American Journal of Preventive Medicine, 2014, 47, 3, 251

    CrossRef

  69. 69
    Adriana Z. Buzatto, Ana Carolina Sousa, Sumaya F. Guedes, Zuzana Cieslarová, Ana Valéria C. Simionato, Metabolomic investigation of human diseases biomarkers by CE and LC coupled to MS, ELECTROPHORESIS, 2014, 35, 9
  70. 70
    S. R. Willis, H. U. Ahmed, C. M. Moore, I. Donaldson, M. Emberton, A. H. Miners, J. van der Meulen, Multiparametric MRI followed by targeted prostate biopsy for men with suspected prostate cancer: a clinical decision analysis, BMJ Open, 2014, 4, 6, e004895

    CrossRef

  71. 71
    Fabio Efficace, Michael Feuerstein, Peter Fayers, Valentina Cafaro, James Eastham, Andrea Pusic, Jane Blazeby, Patient-reported Outcomes in Randomised Controlled Trials of Prostate Cancer: Methodological Quality and Impact on Clinical Decision Making, European Urology, 2014, 66, 3, 416

    CrossRef

  72. 72
    Kathryn J. Martires, David E. Kurlander, Gregory J. Minwell, Eric B. Dahms, Jeremy S. Bordeaux, Patterns of cancer screening in primary care from 2005 to 2010, Cancer, 2014, 120, 2
  73. 73
    Ewan K. Cobran, Anthony K. Wutoh, Euni Lee, Folakemi T. Odedina, Camille Ragin, William Aiken, Paul A. Godley, Perceptions of Prostate Cancer Fatalism and Screening Behavior Between United States-Born and Caribbean-Born Black Males, Journal of Immigrant and Minority Health, 2014, 16, 3, 394

    CrossRef

  74. 74
    Suzanne K. Linder, Michael A. Kallen, Patricia Dolan Mullen, James M. Galliher, Paul R. Swank, Evelyn C. Y. Chan, Robert J. Volk, Physician Behaviors to Promote Informed Decisions for Prostate Cancer Screening: a National Research Network Study, Journal of Cancer Education, 2014, 29, 2, 345

    CrossRef

  75. 75
    Weranja K.B. Ranasinghe, Simon P. Kim, Nathan Lawrentschuk, Shomik Sengupta, Luke Hounsome, Jim Barber, Richard Jones, Paul Davis, Damien Bolton, Raj Persad, Population-based analysis of prostate-specific antigen (PSA) screening in younger men (<55 years) in Australia, BJU International, 2014, 113, 1
  76. 76
    David B. Miller, Pre-Screening Age African-American Males: What Do They Know About Prostate Cancer Screening, Knowledge, and Risk Perceptions?, Social Work in Health Care, 2014, 53, 3, 268

    CrossRef

  77. 77
    Cheng William Hong, Hayet Amalou, Sheng Xu, Baris Turkbey, Pingkun Yan, Jochen Kruecker, Peter A. Pinto, Peter L. Choyke, Bradford J. Wood, Prostate Biopsy for the Interventional Radiologist, Journal of Vascular and Interventional Radiology, 2014, 25, 5, 675

    CrossRef

  78. 78
    Richard M. Hoffman, Jun Li, Jeffrey A. Henderson, Umed A. Ajani, Charles Wiggins, Prostate Cancer Deaths and Incident Cases Among American Indian/Alaska Native Men, 1999–2009, American Journal of Public Health, 2014, 104, S3, S439

    CrossRef

  79. 79
    Sigurdis Haraldsdottir, Heather Hampel, Lai Wei, Christina Wu, Wendy Frankel, Tanios Bekaii-Saab, Albert de la Chapelle, Richard M. Goldberg, Prostate cancer incidence in males with Lynch syndrome, Genetics in Medicine, 2014, 16, 7, 553

    CrossRef

  80. 80
    John W. Ragsdale, Brian Halstater, Viviana Martinez-Bianchi, Prostate Cancer Screening, Primary Care: Clinics in Office Practice, 2014, 41, 2, 355

    CrossRef

  81. 81
    Evelyn M Flahavan, Frances J Drummond, Kathleen Bennett, Thomas I Barron, Linda Sharp, Prostate specific antigen testing is associated with men’s psychological and physical health and their healthcare utilisation in a nationally representative sample: a cross-sectional study, BMC Family Practice, 2014, 15, 1, 121

    CrossRef

  82. 82
    Josef Maryáš, Jakub Faktor, Monika Dvořáková, Iva Struhárová, Peter Grell, Pavel Bouchal, Proteomics in investigation of cancer metastasis: Functional and clinical consequences and methodological challenges, PROTEOMICS, 2014, 14, 4-5
  83. 83
    Suzanne M. Miller, Pagona Roussi, John Scarpato, Kuang-Yi Wen, Fang Zhu, Gem Roy, Randomized trial of print messaging: the role of the partner and monitoring style in promoting provider discussions about prostate cancer screening among African American men, Psycho-Oncology, 2014, 23, 4
  84. 84
    Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?, Genetics in Medicine, 2014, 16, 4, 338

    CrossRef

  85. 85
    Emily A. Vertosick, Bing Ying Poon, Andrew J. Vickers, Relative Value of Race, Family History and Prostate Specific Antigen as Indications for Early Initiation of Prostate Cancer Screening, The Journal of Urology, 2014, 192, 3, 724

    CrossRef

  86. 86
    Cosimo De Nunzio, Riccardo Lombardo, Costantino Leonardo, Giorgio Franco, Mauro Gacci, Fabrizio Presicce, Fabiana Cancrini, Andrea Tubaro, Serum levels of 17-β-estradiol are not predictive of prostate cancer diagnosis and aggressiveness: Results from an Italian biopsy cohort, Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1, 35.e9

    CrossRef

  87. 87
    Inês M. Gomes, Patrícia Arinto, Carlos Lopes, Cecília R. Santos, Cláudio J. Maia, STEAP1 is overexpressed in prostate cancer and prostatic intraepithelial neoplasia lesions, and it is positively associated with Gleason score, Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1, 53.e23

    CrossRef

  88. 88
    George Sgourakis, Aggeliki Papapanagiotou, Christos Kontovounisios, Michalis V. Karamouzis, Georgia Dedemadi, Constantine Goumas, Constantine Karaliotas, Athanasios G. Papavassiliou, The combined use of serum neurotensin and IL-8 as screening markers for colorectal cancer, Tumor Biology, 2014, 35, 6, 5993

    CrossRef

  89. 89
    William P. Tormey, The complexity of PSA interpretation in clinical practice, The Surgeon, 2014, 12, 6, 323

    CrossRef

  90. 90
    Xiaomei Ma, Rong Wang, Jessica B. Long, Joseph S. Ross, Pamela R. Soulos, James B. Yu, Danil V. Makarov, Heather T. Gold, Cary P. Gross, The cost implications of prostate cancer screening in the Medicare population, Cancer, 2014, 120, 1
  91. 91
    Zai-Xian Zhang, Jia Yang, Cheng-Zhong Zhang, Kang-An Li, Qi-Meng Quan, Xi-Fu Wang, Han Wang, Gui-Xiang Zhang, The Value of Magnetic Resonance Imaging in the Detection of Prostate Cancer in Patients with Previous Negative Biopsies and Elevated Prostate-specific Antigen Levels, Academic Radiology, 2014, 21, 5, 578

    CrossRef

  92. 92
    Ruth D. Etzioni, Ian M. Thompson, What Do the Screening Trials Really Tell Us and Where Do We Go From Here?, Urologic Clinics of North America, 2014, 41, 2, 223

    CrossRef

  93. 93
    Steven B Zeliadt, Peggy A Hannon, Ranak B Trivedi, Laura M Bonner, Thuy T Vu, Carol Simons, Crystal A Kimmie, Elaine Y Hu, Chris Zipperer, Daniel W Lin, A preliminary exploration of the feasibility of offering men information about potential prostate cancer treatment options before they know their biopsy results, BMC Medical Informatics and Decision Making, 2013, 13, 1, 19

    CrossRef

  94. 94
    Chris H. Bangma, Meelan Bul, Theo H. van der Kwast, Tom Pickles, Ida J. Korfage, Caroline M. Hoeks, Ewout W. Steyerberg, Guido Jenster, Michael W. Kattan, Lara Bellardita, Peter R. Carroll, Louis J. Denis, Chris Parker, Monique J. Roobol, Mark Emberton, Laurence H. Klotz, Antti Rannikko, Yoshiyuki Kakehi, Janet A. Lane, Fritz H. Schröder, Axel Semjonow, Bruce J. Trock, Riccardo Valdagni, Active surveillance for low-risk prostate cancer, Critical Reviews in Oncology/Hematology, 2013, 85, 3, 295

    CrossRef

  95. 95
    Lois B. Travis, Wendy Demark Wahnefried, James M. Allan, Marie E. Wood, Andrea K. Ng, Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors, Nature Reviews Clinical Oncology, 2013, 10, 5, 289

    CrossRef

  96. 96
    J.-F. Lin, T.-F. Tsai, P.-C. Liao, Y.-H. Lin, Y.-C. Lin, H.-E. Chen, K.-Y. Chou, T. I.-S. Hwang, Benzyl isothiocyanate induces protective autophagy in human prostate cancer cells via inhibition of mTOR signaling, Carcinogenesis, 2013, 34, 2, 406

    CrossRef

  97. You have free access to this content97
    Robert A. Smith, Durado Brooks, Vilma Cokkinides, Debbie Saslow, Otis W. Brawley, Cancer screening in the United States, 2013, CA: A Cancer Journal for Clinicians, 2013, 63, 2
  98. 98
    Michelle E. McDowell, Stefano Occhipinti, Suzanne K. Chambers, Classifying the Reasons Men Consider to be Important in Prostate-Specific Antigen (PSA) Testing Decisions: Evaluating Risks, Lay Beliefs, and Informed Decisions, Annals of Behavioral Medicine, 2013, 46, 3, 322

    CrossRef

  99. You have free access to this content99
    Massimo Lazzeri, Alexander Haese, Alberto Abrate, Alexandre Taille, Joan Palou Redorta, Thomas McNicholas, Giovanni Lughezzani, Giuliana Lista, Alessandro Larcher, Vittorio Bini, Andrea Cestari, Nicolòmaria Buffi, Markus Graefen, Olivier Bosset, Philippe Le Corvoisier, Alberto Breda, Pablo Torre, Linda Fowler, Jacques Roux, Giorgio Guazzoni, Clinical performance of serum prostate-specific antigen isoform [-2]proPSA (p2PSA) and its derivatives, %p2PSA and the prostate health index (PHI), in men with a family history of prostate cancer: results from a multicentre European study, the PROMEtheuS project, BJU International, 2013, 112, 3
  100. 100
    Zakaria Y. Abd Elmageed, Krzysztof Moroz, Emad Kandil, Clinical significance of CD146 and latexin during different stages of thyroid cancer, Molecular and Cellular Biochemistry, 2013, 381, 1-2, 95

    CrossRef

  101. 101
    Sang-Hyun Hwang, Tina Pyo, Heung-Bum Oh, Hyun Jun Park, Kwan-Jeh Lee, Combined application of information theory on laboratory results with classification and regression tree analysis: Analysis of unnecessary biopsy for prostate cancer, Clinica Chimica Acta, 2013, 415, 133

    CrossRef

  102. You have free access to this content102
    Jong J. Oh, Seong J. Jeong, Byung K. Lee, Chang W. Jeong, Seok-Soo Byun, Sung K. Hong, Sang E. Lee, Does obesity affect the accuracy of prostate-specific antigen (PSA) for predicting prostate cancer among men undergoing prostate biopsy, BJU International, 2013, 112, 4
  103. 103
    Tudor Borza, Ramdev Konijeti, Adam S. Kibel, Early Detection, PSA Screening, and Management of Overdiagnosis, Hematology/Oncology Clinics of North America, 2013, 27, 6, 1091

    CrossRef

  104. 104
    Shyam Patel, Muta M. Issa, Rizk El-Galley, Evaluation of Novel Formula of PSA, Age, Prostate Volume, and Race in Predicting Positive Prostate Biopsy Findings, Urology, 2013, 81, 3, 602

    CrossRef

  105. 105
    Ahmet Tefekli, Murat Tunc, Future Prospects in the Diagnosis and Management of Localized Prostate Cancer, The Scientific World Journal, 2013, 2013, 1

    CrossRef

  106. 106
    Linda M. Hunt, Nicole D. Truesdell, Meta J. Kreiner, Genes, Race, and Culture in Clinical Care, Medical Anthropology Quarterly, 2013, 27, 2
  107. 107
    A. Alsuwaida, A. AlSharidi, N. AlAnazi, M. AlGhamdi, M. AlMeshal, R. AlJaser, R. AlAnazi, A. Alkhalaf, Health and well-being among physicians, Internal Medicine Journal, 2013, 43, 12
  108. 108
    V Garg, D W Raisch, J P Selig, T A Thompson, Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis, Prostate Cancer and Prostatic Diseases, 2013,

    CrossRef

  109. 109
    Giuseppe Palermo, Francesco Pinto, Angelo Totaro, Eugenio Miglioranza, Alessandro Calarco, Emilio Sacco, Alessandro Daddessi, Matteo Vittori, Marco Racioppi, Daniele Dagostino, Gaetano Gulino, Mario Giustacchini, Pierfrancesco Bassi, High-intensity focused ultrasound in prostate cancer: Today's outcomes and tomorrow's perspectives, Scandinavian Journal of Urology, 2013, 47, 3, 179

    CrossRef

  110. 110
    Takeo Kosaka, Go Nagamatsu, Shigeru Saito, Mototsugu Oya, Toshio Suda, Katsuhisa Horimoto, Identification of drug candidate against prostate cancer from the aspect of somatic cell reprogramming, Cancer Science, 2013, 104, 8
  111. 111
    Levent Verim, Asif Yildirim, Erem Kaan Basok, Erol Peltekoglu, Eyup Sabri Pelit, Ebru Zemheri, Resit Tokuc, Impact of PSA and DRE on Histologic Findings at Prostate Biopsy in Turkish Men Over 75 Years of Age, Asian Pacific Journal of Cancer Prevention, 2013, 14, 10, 6085

    CrossRef

  112. 112
    Yoon Jae Lee, Ji Eun Park, Byung Ryul Jeon, Sang Moo Lee, Soo Young Kim, You Kyoung Lee, Is Prostate-Specific Antigen Effective for Population Screening of Prostate Cancer? A Systematic Review, Annals of Laboratory Medicine, 2013, 33, 4, 233

    CrossRef

  113. 113
    Ricardo Moreno, Pamela O Delgado, Patrícia G Coelho, Sarah R Marsicano, Viviane AV Boas, Ligia A Azzalis, Virgínia BC Junqueira, Katya C Rocha, Luiz Carlos de Abreu, Vitor E Valenti, Jefferson Drezzet, Edimar Cristiano Pereira, Fernando LA Fonseca, Lack of reliability of nanotechnology in the of free plasma DNA in samples of patients with prostate cancer, International Archives of Medicine, 2013, 6, 1, 2

    CrossRef

  114. 114
    Ruth Etzioni, Roman Gulati, Matt R. Cooperberg, David M. Penson, Noel S. Weiss, Ian M. Thompson, Limitations of Basing Screening Policies on Screening Trials, Medical Care, 2013, 51, 4, 295

    CrossRef

  115. 115
    Siegfried A. Schwab, Michael A. Kuefner, Boris Adamietz, Karl Engelhard, Bastian Keck, Frank Kunath, Sven Wach, Bernd Wullich, Michael Uder, Dirk G. Engehausen, MRI-guided core biopsy of the prostate in the supine position—introduction of a simplified technique using large-bore magnet systems, European Radiology, 2013, 23, 5, 1415

    CrossRef

  116. 116
    Jaime Araujo Oliveira Neto, Daniella Braz Parente, Multiparametric Magnetic Resonance Imaging of the Prostate, Magnetic Resonance Imaging Clinics of North America, 2013, 21, 2, 409

    CrossRef

  117. 117
    Hee Yun Lee, Yunkyung Jung, Older Korean American Men’s Prostate Cancer Screening Behavior: The Prime Role of Culture, Journal of Immigrant and Minority Health, 2013, 15, 6, 1030

    CrossRef

  118. 118
    Morgan Nyberg, Kerstin Ramser, Olof A. Lindahl, Optical fibre probe NIR Raman measurements in ambient light and in combination with a tactile resonance sensor for possible cancer detection, The Analyst, 2013, 138, 14, 4029

    CrossRef

  119. 119
    Christian G. Ramos, Raul Valdevenito, Ivonne Vergara, Patricio Anabalon, Catherine Sanchez, Juan Fulla, PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 8, 1522

    CrossRef

  120. 120
    Linda M. Hunt, Meta J. Kreiner, Pharmacogenetics in Primary Care: The Promise of Personalized Medicine and the Reality of Racial Profiling, Culture, Medicine, and Psychiatry, 2013, 37, 1, 226

    CrossRef

  121. 121
    Yuanyuan Liang, Jamie C. Messer, Christopher Louden, Miguel A. Jimenez-Rios, Ian M. Thompson, Hector R. Camarena-Reynoso, Prostate cancer risk prediction in a urology clinic in Mexico, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 7, 1085

    CrossRef

  122. 122
    Durado D. Brooks, Prostate cancer screening in black men—new questions, few answers, Cancer, 2013, 119, 12
  123. 123
    Mariko Carey, Jamie Bryant, Sze Yoong, Grant Russell, Daniel Barker, Rob Sanson-Fisher, Prostate specific antigen testing in family practice: a cross sectional survey of self-reported rates of and reasons for testing participation and risk disclosure, BMC Family Practice, 2013, 14, 1, 186

    CrossRef

  124. 124
    Hui-Jie Jia, Yang Li, Jin-Guo Wang, Ling Zhang, Hai-Tao Zhang, Xue-Jian Zhao, Masaaki Kuwahara, Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer, Asian Journal of Andrology, 2013, 15, 2, 218

    CrossRef

  125. 125
    J. S. Goodwin, A. Tan, E. Jaramillo, Y.-F. Kuo, Prostate-Specific Antigen Testing in Men Aged 40-64 Years: Impact of Publication of Clinical Trials, JNCI Journal of the National Cancer Institute, 2013, 105, 10, 743

    CrossRef

  126. 126
    Allison S. Glass, K. Clint Cary, Matthew R. Cooperberg, Risk-Based Prostate Cancer Screening: Who and How?, Current Urology Reports, 2013, 14, 3, 192

    CrossRef

  127. 127
    Gustavo Nader Marta, Samir Abdallah Hanna, João Luis Fernandes da Silva, Heloisa de Andrade Carvalho, Screening for prostate cancer: an updated review, Expert Review of Anticancer Therapy, 2013, 13, 1, 101

    CrossRef

  128. 128
    Deepthi Mani, David M. Aboulafia, Screening guidelines for non-AIDS defining cancers in HIV-infected individuals, Current Opinion in Oncology, 2013, 25, 5, 518

    CrossRef

  129. 129
    Daniel S. Wang, Ashesh B. Jani, Caroline G. Tai, Musu Sesay, Daniel K. Lee, Michael Goodman, Katharina V. Echt, Kerry E. Kilbridge, Viraj A. Master, Severe lack of comprehension of common prostate health terms among low-income inner-city men, Cancer, 2013, 119, 17
  130. 130
    C. Lao, C. Brown, Z. Obertova, R. Edlin, P. Rouse, F. Hodgson, M. Holmes, P. Gilling, R. Lawrenson, The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice, Family Practice, 2013, 30, 6, 641

    CrossRef

  131. 131
    B. T. Howrey, Y.-F. Kuo, Y.-L. Lin, J. S. Goodwin, The Impact of PSA Screening on Prostate Cancer Mortality and Overdiagnosis of Prostate Cancer in the United States, The Journals of Gerontology Series A: Biological Sciences and Medical Sciences, 2013, 68, 1, 56

    CrossRef

  132. 132
    Yuanyuan Liang, Donna P. Ankerst, Ziding Feng, Rong Fu, Janet L. Stanford, Ian M. Thompson, The risk of biopsy-detectable prostate cancer using the prostate cancer prevention Trial Risk Calculator in a community setting, Urologic Oncology: Seminars and Original Investigations, 2013, 31, 8, 1464

    CrossRef

  133. 133
    A. Mestre-Fusco, M. Suárez-Piñera, Use of choline tracers in the prostate carcinoma management, Médecine Nucléaire, 2013, 37, 3, 71

    CrossRef

  134. You have free access to this content134
    Masahito Jimbo, Gurpreet K. Rana, Sarah Hawley, Margaret Holmes-Rovner, Karen Kelly-Blake, Donald E. Nease, Mack T. Ruffin, What is lacking in current decision aids on cancer screening?, CA: A Cancer Journal for Clinicians, 2013, 63, 3
  135. 135
    Cosimo De Nunzio, Costantino Leonardo, Giorgio Franco, Francesco Esperto, Aldo Brassetti, Giovanni Simonelli, Dino Dente, Carlo De Dominicis, Andrea Tubaro, When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool, World Journal of Urology, 2013, 31, 2, 365

    CrossRef

  136. 136
    Laia Agell, Silvia Hernández, Lara Nonell, Marta Lorenzo, Eulàlia Puigdecanet, Silvia de Muga, Nuria Juanpere, Raquel Bermudo, Pedro L. Fernández, José A. Lorente, Sergio Serrano, Josep Lloreta, A 12-Gene Expression Signature Is Associated with Aggressive Histological in Prostate Cancer, The American Journal of Pathology, 2012, 181, 5, 1585

    CrossRef

  137. 137
    Xiaozhi Zheng, Ping Ji, Hongwei Mao, Jianqun Hu, A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia, Radiology and Oncology, 2012, 46, 1

    CrossRef

  138. 138
    Mohan Adhyam, Anish Kumar Gupta, A Review on the Clinical Utility of PSA in Cancer Prostate, Indian Journal of Surgical Oncology, 2012, 3, 2, 120

    CrossRef

  139. 139
    Alison Tradonsky, Tammy Rubin, Rodney Beck, Brian Ring, Robert Seitz, Sharon Mair, A Search for Reliable Molecular Markers of Prognosis in Prostate Cancer, American Journal of Clinical Pathology, 2012, 137, 6, 918

    CrossRef

  140. 140
    Simon P. Kim, R. Jeffrey Karnes, An Editorial Response to the USPTF, Journal of Men's Health, 2012, 9, 1, 5

    CrossRef

  141. 141
    Xiao Wang, Shuai Wang, Yi-wei Lin, Jian Wu, Hong Chen, Ye-qing Mao, Xiang-yi Zheng, Cheng Zhou, Li-ping Xie, Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China, Medical Oncology, 2012, 29, 3, 1964

    CrossRef

  142. 142
    J. R. Prensner, M. A. Rubin, J. T. Wei, A. M. Chinnaiyan, Beyond PSA: The Next Generation of Prostate Cancer Biomarkers, Science Translational Medicine, 2012, 4, 127, 127rv3

    CrossRef

  143. You have free access to this content143
    Robert A. Smith, Vilma Cokkinides, Otis W. Brawley, Cancer screening in the United States, 2012, CA: A Cancer Journal for Clinicians, 2012, 62, 2
  144. 144
    C. Neppl-Huber, M. Zappa, J. W. Coebergh, E. Rapiti, J. Rachtan, B. Holleczek, S. Rosso, T. Aareleid, H. Brenner, A. Gondos, Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths, Annals of Oncology, 2012, 23, 5, 1325

    CrossRef

  145. 145
    Hank Dart, Kathleen Y. Wolin, Graham A. Colditz, Commentary: eight ways to prevent cancer: a framework for effective prevention messages for the public, Cancer Causes & Control, 2012, 23, 4, 601

    CrossRef

  146. 146
    Michael B. Nichol, Joanne Wu, Joice Huang, Dwight Denham, Stanley K. Frencher, Steven J. Jacobsen, Cost-effectiveness of Prostate Health Index for prostate cancer detection, BJU International, 2012, 110, 3
  147. 147
    Donna F. Timm, Daniel E. Banks, Jerry McLarty, Critical Appraisal Process, Southern Medical Journal, 2012, 105, 3, 144

    CrossRef

  148. 148
    Martijn Smeenge, Jean J.M.C.H. de la Rosette, Hessel Wijkstra, Current status of transrectal ultrasound techniques in prostate cancer, Current Opinion in Urology, 2012, 22, 4, 297

    CrossRef

  149. 149
    Po-Yuan Lin, Kai-Lun Cheng, James D. McGuffin-Cawley, Fuh-Sheng Shieu, Anna C. Samia, Sanjay Gupta, Matthew Cooney, Cheryl L. Thompson, Chung Chiun Liu, Detection of Alpha-Methylacyl-CoA Racemase (AMACR), a Biomarker of Prostate Cancer, in Patient Blood Samples Using a Nanoparticle Electrochemical Biosensor, Biosensors, 2012, 2, 4, 377

    CrossRef

  150. 150
    Jona A. Hattangadi, Ming-Hui Chen, Anthony V. D'Amico, Early detection of high-grade prostate cancer using digital rectal examination (DRE) in men with a prostate-specific antigen level of <2.5 ng/mL and the risk of death, BJU International, 2012, 110, 11
  151. 151
    R. Cortese, A. Kwan, E. Lalonde, O. Bryzgunova, A. Bondar, Y. Wu, J. Gordevicius, M. Park, G. Oh, Z. Kaminsky, J. Tverkuviene, A. Laurinavicius, F. Jankevicius, D. H. S. Sendorek, S. Haider, S.-C. Wang, S. Jarmalaite, P. Laktionov, P. C. Boutros, A. Petronis, Epigenetic markers of prostate cancer in plasma circulating DNA, Human Molecular Genetics, 2012, 21, 16, 3619

    CrossRef

  152. 152
    Anthony N. Hoang, Dmitry Volkin, Nitin K. Yerram, Srinivas Vourganti, Jeffrey Nix, W. Marston Linehan, Bradford Wood, Peter A. Pinto, Image guidance in the focal treatment of prostate cancer, Current Opinion in Urology, 2012, 22, 4, 328

    CrossRef

  153. 153
    Mary A. Hall, Sunkuk Kwon, Holly Robinson, Pier-Anne Lachance, Ali Azhdarinia, Ranjani Ranganathan, Roger E. Price, Wenyaw Chan, Eva M. Sevick-Muraca, Imaging prostate cancer lymph node metastases with a multimodality contrast agent, The Prostate, 2012, 72, 2
  154. 154
    Stephen J. Lepore, Randi L. Wolf, Charles E. Basch, Melissa Godfrey, Emma McGinty, Celia Shmukler, Ralph Ullman, Nigel Thomas, Sally Weinrich, Informed Decision Making About Prostate Cancer Testing in Predominantly Immigrant Black Men: A Randomized Controlled Trial, Annals of Behavioral Medicine, 2012, 44, 3, 320

    CrossRef

  155. 155
    Fritz H. Schröder, Landmarks in prostate cancer screening, BJU International, 2012, 110,
  156. 156
    Shannon Kahn, Ashesh Jani, Scott Edelman, Peter Rossi, Karen Godette, Jerome Landry, Cynthia Anderson, Matched Cohort Analysis of Outcomes of Definitive Radiotherapy for Prostate Cancer in Human Immunodeficiency Virus-Positive Patients, International Journal of Radiation Oncology*Biology*Physics, 2012, 83, 1, 16

    CrossRef

  157. 157
    Angela Chan, Blake Gilks, Janice Kwon, Anna V. Tinker, New Insights Into the Pathogenesis of Ovarian Carcinoma, Obstetrics & Gynecology, 2012, 120, 4, 935

    CrossRef

  158. 158
    Kyung Kgi Park, Seung Hwan Lee, Young Deuk Choi, Byung Ha Chung, Optimal Baseline Prostate-Specific Antigen Level to Distinguish Risk of Prostate Cancer in Healthy Men Between 40 and 69 Years of Age, Journal of Korean Medical Science, 2012, 27, 1, 40

    CrossRef

  159. You have free access to this content159
    Michelle E. McDowell, Stefano Occhipinti, Robert A. Gardiner, Suzanne K. Chambers, Patterns of prostate-specific antigen (PSA) testing in Australian men: the influence of family history, BJU International, 2012, 109,
  160. 160
    J. L. Donovan, Presenting Treatment Options to Men with Clinically Localized Prostate Cancer: The Acceptability of Active Surveillance/Monitoring, JNCI Monographs, 2012, 2012, 45, 191

    CrossRef

  161. 161
    Harcharan Gill, Jonathan Wu, Prostate Specific Antigen:The Past, Present and Future, Current Urology, 2012, 6, 4, 175

    CrossRef

  162. 162
    Amanda Black, Christine D. Berg, Prostate-Specific Antigen Screening for Prostate Cancer in Older Men in the United States of America, Gerontology, 2012, 58, 4, 331

    CrossRef

  163. 163
    Emil Scosyrev, Guan Wu, Dragan Golijanin, Edward Messing, Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system, BJU International, 2012, 110, 10
  164. 164
    G E Tasian, M R Cooperberg, M B Potter, J E Cowan, K L Greene, P R Carroll, J M Chan, PSA screening: determinants of primary-care physician practice patterns, Prostate Cancer and Prostatic Diseases, 2012, 15, 2, 189

    CrossRef

  165. 165
    Jun Li, Joseph A. Djenaba, Ashwini Soman, Sun Hee Rim, Viraj A. Master, Recent Trends in Prostate Cancer Incidence by Age, Cancer Stage, and Grade, the United States, 2001–2007, Prostate Cancer, 2012, 2012, 1

    CrossRef

  166. 166
    Ashwin A. Kotwal, Supriya G. Mohile, William Dale, Remaining life expectancy measurement and PSA screening of older men, Journal of Geriatric Oncology, 2012, 3, 3, 196

    CrossRef

  167. 167
    Monique J. Roobol, Sigrid V. Carlsson, Risk stratification in prostate cancer screening, Nature Reviews Urology, 2012, 10, 1, 38

    CrossRef

  168. 168
    Xiaoye Zhu, Peter C. Albertsen, Gerald L. Andriole, Monique J. Roobol, Fritz H. Schröder, Andrew J. Vickers, Risk-Based Prostate Cancer Screening, European Urology, 2012, 61, 4, 652

    CrossRef

  169. 169
    Leslie Oleksowicz, Yin Liu, R. Bruce Bracken, Krishnanath Gaitonde, Barbara Burke, Paul Succop, Linda Levin, Zhongyun Dong, Shan Lu, Secretory phospholipase A2-IIa is a target gene of the HER/HER2-elicited pathway and a potential plasma biomarker for poor prognosis of prostate cancer, The Prostate, 2012, 72, 10
  170. 170
    Michael J. Barry, Shared Decision Making, Journal of Ambulatory Care Management, 2012, 35, 2, 90

    CrossRef

  171. 171
    Stacey L Sheridan, Carol Golin, Audrina Bunton, John B Lykes, Bob Schwartz, Lauren McCormack, David Driscoll, Shrikant I Bangdiwala, Russell P Harris, Shared decision making for prostate cancer screening: the results of a combined analysis of two practice-based randomized controlled trials, BMC Medical Informatics and Decision Making, 2012, 12, 1, 130

    CrossRef

  172. 172
    Daniel J. Underwood, Jingyu Zhang, Brian T. Denton, Nilay D. Shah, Brant A. Inman, Simulation optimization of PSA-threshold based prostate cancer screening policies, Health Care Management Science, 2012, 15, 4, 293

    CrossRef

  173. 173
    Leander Van Neste, James G Herman, Gaëtan Otto, Joseph W Bigley, Jonathan I Epstein, Wim Van Criekinge, The Epigenetic promise for prostate cancer diagnosis, The Prostate, 2012, 72, 11
  174. 174
    Ashwin A. Kotwal, Phil Schumm, Supriya G. Mohile, William Dale, The Influence of Stress, Depression, and Anxiety on PSA Screening Rates in a Nationally Representative Sample, Medical Care, 2012, 50, 12, 1037

    CrossRef

  175. 175
    Yuanyuan Liang, Norma S. Ketchum, Christopher Louden, Miguel A. Jimenez-Rios, Ian M. Thompson, Hector R. Camarena-Reynoso, The Use of the Finasteride-Adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican Referral Population: A Validation Study, Urologia Internationalis, 2012, 89, 1, 9

    CrossRef

  176. 176
    E M Wever, J Hugosson, E A M Heijnsdijk, C H Bangma, G Draisma, H J de Koning, To be screened or not to be screened? Modeling the consequences of PSA screening for the individual, British Journal of Cancer, 2012, 107, 5, 778

    CrossRef

  177. 177
    Donna P. Ankerst, Tim Koniarski, Yuanyuan Liang, Robin J. Leach, Ziding Feng, Martin G. Sanda, Alan W. Partin, Daniel W. Chan, Jacob Kagan, Lori Sokoll, John T. Wei, Ian M. Thompson, Updating risk prediction tools: A case study in prostate cancer, Biometrical Journal, 2012, 54, 1
  178. 178
    Lori J. Sokoll, Alex J. Rai, Daniel W. Chan, Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, 2012,

    CrossRef

  179. 179
    Evelyn C.Y. Chan, Stephanie L. McFall, Theresa L. Byrd, Patricia Dolan Mullen, Robert J. Volk, John Ureda, Jessica Calderon-Mora, Pat Morales, Adriana Valdes, L. Kay Bartholomew, A community-based intervention to promote informed decision making for prostate cancer screening among Hispanic American men changed knowledge and role preferences: A cluster RCT, Patient Education and Counseling, 2011, 84, 2, e44

    CrossRef

  180. 180
    David C Wheeler, Konrad M Szymanski, Amanda Black, David E Nelson, Applying strategies from libertarian paternalism to decision making for prostate specific antigen (PSA) screening, BMC Cancer, 2011, 11, 1, 148

    CrossRef

  181. 181
    Johannes W. Pedersen, Hans H. Wandall, Autoantibodies as Biomarkers in Cancer, Laboratory Medicine, 2011, 42, 10, 623

    CrossRef

  182. 182
    M B Nichol, J Wu, J J An, J Huang, D Denham, S Frencher, S J Jacobsen, Budget impact analysis of a new prostate cancer risk index for prostate cancer detection, Prostate Cancer and Prostatic Diseases, 2011, 14, 3, 253

    CrossRef

  183. 183
    Shabbir M.H. Alibhai, Anne M. Horgan, Cancer screening in older adults: What to do when we don't know, Journal of Geriatric Oncology, 2011, 2, 3, 149

    CrossRef

  184. You have free access to this content184
    Robert A. Smith, Vilma Cokkinides, Durado Brooks, Debbie Saslow, Mona Shah, Otis W. Brawley, Cancer screening in the United States, 2011, CA: A Cancer Journal for Clinicians, 2011, 61, 1
  185. 185
    Yu-Ning Wong, Elliot J. Coups, Correlates of Colorectal Cancer Screening Adherence Among Men Who have been Screened for Prostate Cancer, Journal of Cancer Education, 2011, 26, 2, 301

    CrossRef

  186. 186
    Ingrid J. Hall, Yhenneko J. Taylor, Louie E. Ross, Lisa C. Richardson, Thomas B. Richards, Sun Hee Rim, Discussions About Prostate Cancer Screening Between U.S. Primary Care Physicians and Their Patients, Journal of General Internal Medicine, 2011, 26, 10, 1098

    CrossRef

  187. 187
    Jeanne M. Ferrante, Eric K. Shaw, John G. Scott, Factors Influencing Men’s Decisions Regarding Prostate Cancer Screening: A Qualitative Study, Journal of Community Health, 2011, 36, 5, 839

    CrossRef

  188. 188
    Francesco Pinto, Angelo Totaro, Alessandro Calarco, Emilio Sacco, Andrea Volpe, Marco Racioppi, Alessandro D’Addessi, Gaetano Gulino, PierFrancesco Bassi, Imaging in Prostate Cancer Diagnosis: Present Role and Future Perspectives, Urologia Internationalis, 2011, 86, 4, 373

    CrossRef

  189. 189
    Joanne M. Harrington, Implications of Treatment on Body Image and Quality of Life, Seminars in Oncology Nursing, 2011, 27, 4, 290

    CrossRef

  190. 190
    Suk Kyong Cho, Joon Young Choi, Jang Yoo, Miju Cheon, Ji Young Lee, Seung Hyup Hyun, Eun Jeong Lee, Kyung-Han Lee, Byung-Tae Kim, Incidental Focal 18F-FDG Uptake in the Prostate: Clinical Significance and Differential Diagnostic Criteria, Nuclear Medicine and Molecular Imaging, 2011, 45, 3, 192

    CrossRef

  191. 191
    Margaritis Avgeris, Konstantinos Stravodimos, Andreas Scorilas, Kallikrein-related peptidase 4 gene (KLK4) in prostate tumors: Quantitative expression analysis and evaluation of its clinical significance, The Prostate, 2011, 71, 16
  192. 192
    Eva Johansson, Gunnar Steineck, Lars Holmberg, Jan-Erik Johansson, Tommy Nyberg, Mirja Ruutu, Anna Bill-Axelson, Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial, The Lancet Oncology, 2011, 12, 9, 891

    CrossRef

  193. 193
    Johannes Kurth, Elita DeFeo, Leo L. Cheng, Magnetic resonance spectroscopy: A promising tool for the diagnostics of human prostate cancer?, Urologic Oncology: Seminars and Original Investigations, 2011, 29, 5, 562

    CrossRef

  194. 194
    Cosimo De Nunzio, Stephen J Freedland, Roberto Miano, Alberto Trucchi, Andrea Cantiani, Alfonso Carluccini, Andrea Tubaro, Metabolic syndrome is associated with high grade gleason score when prostate cancer is diagnosed on biopsy, The Prostate, 2011, 71, 14
  195. 195
    Robert M. Taylor, Dale L. Huber, Todd C. Monson, Abdul-Mehdi S. Ali, Marco Bisoffi, Laurel O. Sillerud, Multifunctional iron platinum stealth immunomicelles: targeted detection of human prostate cancer cells using both fluorescence and magnetic resonance imaging, Journal of Nanoparticle Research, 2011, 13, 10, 4717

    CrossRef

  196. 196
    Mary F. McNaughton-Collins, Michael J. Barry, One Man at a Time — Resolving the PSA Controversy, New England Journal of Medicine, 2011, 365, 21, 1951

    CrossRef

  197. 197
    Michaela Strobelberger, Angela Kaminski, Gerald Gartlehner, Österreichische Patienteninformationsmaterialien zu PSA-Screening entsprechen nicht internationalen evidenzbasierten Standards, Wiener Medizinische Wochenschrift, 2011, 161, 3-4, 89

    CrossRef

  198. You have free access to this content198
    C. Stewart Rogers, Perspective on prostate cancer screening, International Journal of Clinical Practice, 2011, 65, 1
  199. 199
    D I Chu, C De Nunzio, L Gerber, J-A Thomas, E E Calloway, S Albisinni, C Senocak, M G McKeever, D M Moreira, A Tubaro, J W Moul, S J Freedland, L L Bañez, Predictive value of digital rectal examination for prostate cancer detection is modified by obesity, Prostate Cancer and Prostatic Diseases, 2011, 14, 4, 346

    CrossRef

  200. 200
    Ted A. Skolarus, Margaret Holmes-Rovner, Laurel L. Northouse, Angela Fagerlin, Carol Garlinghouse, Raymond Y. Demers, David R. Rovner, May Darwish-Yassine, John T. Wei, Primary care perspectives on Prostate cancer screening, The Nurse Practitioner, 2011, 36, 6, 39

    CrossRef

  201. You have free access to this content201
    Mona Sarfaty, Richard Wender, Robert Smith, Promoting cancer screening within the patient centered medical home, CA: A Cancer Journal for Clinicians, 2011, 61, 6
  202. 202
    Yuanyuan Liang, Donna P. Ankerst, Norma S. Ketchum, Barbara Ercole, Girish Shah, John D. Shaughnessy, Robin J. Leach, Ian M. Thompson, Prospective Evaluation of Operating Characteristics of Prostate Cancer Detection Biomarkers, The Journal of Urology, 2011, 185, 1, 104

    CrossRef

  203. 203
    Elise D. Cook, Ana C. Nelson, Prostate Cancer Screening, Current Oncology Reports, 2011, 13, 1, 57

    CrossRef

  204. 204
    Allan S. Brett, Richard J. Ablin, Prostate-Cancer Screening — What the U.S. Preventive Services Task Force Left Out, New England Journal of Medicine, 2011, 365, 21, 1949

    CrossRef

  205. 205
    David A Leavitt, Badrinath R Konety, Prostate-specific antigen screening in elderly men, Aging Health, 2011, 7, 2, 219

    CrossRef

  206. 206
    Chris Cain, Prostate's PTEN prognosis, Science-Business eXchange, 2011, 4, 9

    CrossRef

  207. 207
    Lionne DF Venderbos, Monique J Roobol, PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making, Asian Journal of Andrology, 2011, 13, 2, 219

    CrossRef

  208. 208
    Hon-Cheong So, Johnny S.H. Kwan, Stacey S. Cherny, Pak C. Sham, Risk Prediction of Complex Diseases from Family History and Known Susceptibility Loci, with Applications for Cancer Screening, The American Journal of Human Genetics, 2011, 88, 5, 548

    CrossRef

  209. 209
    Richard M. Hoffman, Screening for Prostate Cancer, New England Journal of Medicine, 2011, 365, 21, 2013

    CrossRef

  210. 210
    Dominick L. Frosch, Benjamin W. Moulton, Richard M. Wexler, Margaret Holmes-Rovner, Robert J. Volk, Carrie A. Levin, Shared decision making in the United States: policy and implementation activity on multiple fronts, Zeitschrift für Evidenz, Fortbildung und Qualität im Gesundheitswesen, 2011, 105, 4, 305

    CrossRef

  211. 211
    Isabelle Vedel, Martine T.E. Puts, Michele Monette, Johanne Monette, Howard Bergman, The decision-making process in prostate cancer screening in primary care with a prostate-specific antigen: A systematic review, Journal of Geriatric Oncology, 2011, 2, 3, 161

    CrossRef

  212. 212
    Mengqian Chen, Richard Carkner, Ralph Buttyan, The hedgehog/Gli signaling paradigm in prostate cancer, Expert Review of Endocrinology & Metabolism, 2011, 6, 3, 453

    CrossRef

  213. 213
    Maureen E. O'Rourke, The Prostate-Specific Antigen Screening Conundrum: Examining the Evidence, Seminars in Oncology Nursing, 2011, 27, 4, 251

    CrossRef

  214. 214
    C. De Nunzio, S.J. Freedland, L. Miano, E. Finazzi Agrò, L. Bañez, A. Tubaro, The uncertain relationship between obesity and prostate cancer: An Italian biopsy cohort analysis, European Journal of Surgical Oncology (EJSO), 2011, 37, 12, 1025

    CrossRef

  215. 215
    Lauren McCormack, Katherine Treiman, Carla Bann, Pamela Williams-Piehota, David Driscoll, Jon Poehlman, Cindy Soloe, Kathleen Lohr, Stacey Sheridan, Carol Golin, Samuel Cykert, Russell Harris, Translating Medical Evidence to Promote Informed Health Care Decisions, Health Services Research, 2011, 46, 4
  216. 216
    Idethia Shevon Harvey, Reginald J. Alston, Understanding preventive behaviors among mid-Western African-American men: a pilot qualitative study of prostate screening, Journal of Men's Health, 2011, 8, 2, 140

    CrossRef

  217. 217
    Carl K. Gjertson, Peter C. Albertsen, Use and Assessment of PSA in Prostate Cancer, Medical Clinics of North America, 2011, 95, 1, 191

    CrossRef

  218. 218
    Yu-Kuan Lin, Lori Gettle, Jay D. Raman, Variable Prostate-specific Antigen Management Patterns by Nonurologist Providers at a Tertiary Care Medical Center, Urology, 2011, 78, 2, 244

    CrossRef

  219. 219
    Richard M Hoffman, Anthony Y Smith, What we have learned from randomized trials of prostate cancer screening, Asian Journal of Andrology, 2011, 13, 3, 369

    CrossRef

  220. 220
    Ji-Fan Lin, Yi-Chia Lin, Yi-Hsuan Lin, Te-Fu Tsai, Kuang-Yu Chou, Hung-En Chen, Thomas I-Sheng Hwang, Zoledronic Acid Induces Autophagic Cell Death in Human Prostate Cancer Cells, The Journal of Urology, 2011, 185, 4, 1490

    CrossRef

  221. 221
    Durado D. Brooks, Andrew M.D. Wolf, Robert A. Smith, Chiranjeev Dash, Idris Guessous, Prostate Cancer Screening 2010: Updated Recommendations From the American Cancer Society, Journal of the National Medical Association, 2010, 102, 5, 423

    CrossRef

  222. 222
    P. Mongiat-Artus, F. Desgrandchamps, PSA (antigène spécifique de la prostate) : la langue d’Ésope ?, La Revue de Médecine Interne, 2010, 31, 7, 467

    CrossRef

  223. 223
    Reply by Authors, The Journal of Urology, 2010, 184, 4, 1572

    CrossRef

  224. 224
    Steven B. Zeliadt, Richard M. Hoffman, Ruth Etzioni, Van Anh T. Ginger, Daniel W. Lin, What Happens After an Elevated PSA Test: The Experience of 13,591 Veterans, Journal of General Internal Medicine, 2010, 25, 11, 1205

    CrossRef

  225. 225
    Yiannis Philippou, Harveer Dev, Prasanna Sooriakumaran, Diagnosis and Screening,
  226. 226
    Frank Peinemann, Ulrich Grouven, Carmen Bartel, Holger Borchers, Michael Pinkawa, Axel Heidenreich, Lars G Hemkens, Petra Schnell-Inderst, Rebecca Jahn, Stefan Sauerland, Low-dose rate brachytherapy for men with localized prostate cancer, The Cochrane Library,
  227. 227
    Frank Peinemann, Ulrich Grouven, Lars G Hemkens, Carmen Bartel, Holger Borchers, Michael Pinkawa, Axel Heidenreich, Stefan Sauerland, Low-dose rate brachytherapy for men with localized prostate cancer, The Cochrane Library,